Drug Profile
Omalizumab biosimilar - Glenmark Pharmaceuticals
Alternative Names: GBR 310Latest Information Update: 24 Nov 2021
Price :
$50
*
At a glance
- Originator Glenmark Pharmaceuticals Ltd
- Class Antiallergics; Antiasthmatics; Monoclonal antibodies; Skin disorder therapies
- Mechanism of Action IgE receptor antagonists; Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Allergic asthma; Chronic urticaria
Most Recent Events
- 16 Mar 2021 Phase II development for Chronic-urticaria and Allergic asthma is still ongoing in USA (Glenmark Pharmaceuticals pipeline, March 2021)
- 08 Jan 2019 Phase-II clinical trials in Allergic asthma in USA (SC) before January 2019 (Glenmark Pharmaceuticals pipeline, January 2019)
- 08 Jan 2019 Phase-II clinical trials in Chronic-urticaria in USA (SC) before January 2019 (Glenmark Pharmaceuticals pipeline, January 2019)